Sabby Management’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Sabby Management’s Portfolio DMK Stock Details DMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,260	Closed	-$32K	–	130
2020 Q1	$32K	Buy	+1,260	New	+$53.5K	0.01%	77
2019 Q4	–	Sell	-2,619	Closed	-$127K	–	96
2019 Q3	$129K	Buy	+2,619	New	+$188K	0.07%	74
2017 Q4	–	Sell	-1,434	Closed	-$524K	–	193
2017 Q3	$524K	Buy	+1,434	New	+$509K	0.03%	98
2014 Q2	–	Sell	-868	Closed	-$386K	–	293
2014 Q1	$386K	Sell	868 -4,947	-85%	-$2.24M	0.02%	187
2013 Q4	$2.6M	Buy	+5,815	New	+$2.55M	0.17%	70

Other funds holding DMK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Edmond de Rothschild Holding Chambesy, Switzerland $7.59B AUM 23.44% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sabby Management's DMK Position: Q2 2020 in Review

Sabby Management sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q2 2020, closing a stake of 1,260 shares — an estimated $32K sold.

Sabby Management first reported a position in DMK in Q4 2013 and held it in 5 quarters. The position peaked at $2.6M in Q4 2013. 47 funds tracked by Wall St. Rank hold DMK as of Q2 2020.

Sabby Management reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q2 2020 after selling out during the quarter.
Sabby Management sold 1,260 DMK Pharmaceuticals Corporation Common Stock shares in Q2 2020, an estimated $32K.
Sabby Management first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q4 2013 and held it in 5 quarters.
Sabby Management's DMK Pharmaceuticals Corporation Common Stock position peaked at $2.6M in Q4 2013.
47 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q2 2020.

Based on Sabby Management's 13F filing for Q2 2020, filed 14 Aug 2020.